Le présent article, issu d’une table ronde tenue lors des Rencontres de l’IMIC en octobre 2025, explore la neuro-phénoménologie, une approche articulant l’expérience subjective (première personne) et les mesures objectives issues des neurosciences (troisième personne). Elle vise à relier les vécus à leurs corrélats cérébraux en hypnose et en méditation. À l’issue de ces échanges retranscrits...
This article reviews the current clinical evidence for psilocybin and ayahuasca as therapeutic agents, examining data from over 134 registered clinical trials and key publications in the New England Journal of Medicine, JAMA, JAMA Psychiatry, and Nature Neuroscience. The review addresses four dimensions: (1) the state of clinical evidence for psilocybin and ayahuasca in major depression and...
Research SquareApril 1, 2026Simay Selek, Russell W Chan, Funda Yildirim
preprint
Abstract Meditation is increasingly recognized as a structured form of mental training that can induce plastic changes in neural systems supporting attention, cognitive control, and affect regulation. Although prior work links meditation to improved executive functioning, few studies have examined attentional performance under simultaneous cognitive conflict and emotional distraction. This...
The interplay between cAMP/PKA and neuroplasticity involves intricate signaling pathways that are crucial for brain function and are frequently disrupted in schizophrenia. This study sought to examine the potential neuroprotective effects of formoterol on ketamine-induced schizophrenia-like behaviors with emphasis on several PKA downstream crucial targets for schizophrenia management. Male mice...
Psilocybin, a serotonergic psychedelic, has gained attention as a potential treatment for various psychiatric conditions. In this review, the authors summarize current clinical evidence related to psilocybin’s efficacy, safety, and mechanisms of action across psychiatric disorders. Findings from early-phase and small-scale clinical trials suggest rapid but variable reductions in depressive...
Major depressive disorder (MDD) imposes a substantial burden worldwide, with treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI) representing two of the most severe clinical challenges. Conventional antidepressants often require several weeks to exert benefit, leaving patients symptomatic and at risk during this delay. Esketamine...
Intimate partner violence (IPV) poses a significant medical concern, predominantly affecting females. IPV-related brain injuries (IPV-BI), such as mild traumatic brain injury (mTBI) and non-fatal strangulation (NFS), sustained during physical attacks are common and often repetitive. Chronic neurobehavioral sequalae from IPV-BI are associated with neuroinflammation and impaired neuroplasticity,...
Obsessive–compulsive disorder (OCD) is a psychiatric condition with high rates of treatment resistance. Emerging neuroimaging evidence implicates dysfunction in large-scale brain networks, particularly the cortico–striatal–thalamo–cortical (CSTC) circuit, default mode network (DMN) and salience network (SN). Lysergic acid diethylamide (LSD) and psilocybin induce acute dysregulation of the DMN...
Major Depressive Disorder (MDD) and chronic pain are independently debilitating conditions that frequently co-occur. This comorbidity poses a significant clinical challenge, resulting in greater symptom severity, higher disability, and worse prognosis than either condition alone. Current therapies often address each disorder in isolation, leaving individuals with comorbid MDD and chronic pain...
Frontiers in NeurologyMarch 30, 2026Jose E. Leon-Rojas, Guido Mascialino, Lizeth Vinueza Mera et al.2 citations
Subanesthetic ketamine shows rapid neuroplastic and antidepressant effects in psychiatric conditions, prompting interest in its potential relevance for cognitive dysfunction in neurological disorders. Cognitive deficits are widespread across traumatic brain injury, stroke, epilepsy, and neurodegenerative diseases, yet treatments remain primarily compensatory. Ketamine's actions on glutamatergic...